Par Pharmaceutical
Executive Summary
Pleads guilty Dec. 6 in Baltimore federal court to 10 criminal violations related to the company's falsification of ANDA applications in 1986-87, its use of unapproved ingredients or deviations from approved ANDA manufacturing methods and the obstruction of an FDA inspection. Par received a $ 2.5 mil. criminal fine. Par parent Pharmaceutical Resources had said on Nov. 21 that the company would plead guilty ("The Pink Sheet" Nov. 25, T&G-15).